Decheng Capital Management Iii (Cayman), LLC Arcus Biosciences, Inc. Transaction History
Decheng Capital Management Iii (Cayman), LLC
- $181 Million
- Q3 2023
A detailed history of Decheng Capital Management Iii (Cayman), LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Decheng Capital Management Iii (Cayman), LLC holds 869,790 shares of RCUS stock, worth $13.2 Million. This represents 8.64% of its overall portfolio holdings.
Number of Shares
869,790
Previous 869,790
-0.0%
Holding current value
$13.2 Million
Previous $17.7 Million
11.62%
% of portfolio
8.64%
Previous 9.36%
Shares
2 transactions
Others Institutions Holding RCUS
# of Institutions
186Shares Held
49.2MCall Options Held
204KPut Options Held
149K-
Black Rock Inc. New York, NY9.9MShares$151 Million0.0% of portfolio
-
State Street Corp Boston, MA4.9MShares$74.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.79MShares$73 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA2.88MShares$43.9 Million0.52% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.91MShares$29.2 Million0.09% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.1B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...